Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.
Read Original Story

‘Game-changer, Holy Grail, groundbreaking’ used in Philly Inquirer story on phase 1 trial

Rating

3 Star

Tags

Novel therapy for rare eye cancer holds promise for targeting other tumors

Our Review Summary

This story suggests that an experimental drug being tested in an early, small trial for eye cancer could “pave the way for a new class of exquisitely precise cancer therapies” that might be used in a wide variety of cancers.

Although the story does include a paragraph noting how much research remains to be done before the drug’s developer could even apply for FDA approval, the tone includes the type of language journalists generally are urged to avoid. The first two paragraphs suggest that the experimental drug might represent “the Holy Grail of cancer researchers,” a drug that kills cancer cells without damaging healthy tissue, and the third paragraph quotes one of the researchers saying, “This could be a game-changer if it works.”

The story cannot quantify benefits because the research hasn’t yet established what those benefits might be; it also cannot explain harms because the clinical trial it focuses on is meant to test the safety of the drug.

 

Why This Matters

As promising as this new approach might be, this story doesn’t acknowledge the inadequacy of the available evidence supporting the drug’s use.

Criteria

Does the story adequately discuss the costs of the intervention?

Not Satisfactory

The story provides no information about costs, in part because the patient who is the focus of the story was participating in a clinical trial and likely received the treatment at no cost. Even if that was the case, however, the story should have discussed how much this type of treatment would cost, if it became available outside the context of a clinical trial.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

Because the story deals with one patient who is participating in an early stage clinical trial, there is little concrete benefit information to report. The story says that the doctor conducting the clinical trial found, a month after the first treatment, that this first patient’s tumor “had begun to atrophy,” but it notes that data from animal trials of the drug suggest that it would take “three or four months to gauge the response.” The bottom line here is that because the story focuses on the first human patient in the earliest of three levels of clinical trials required for FDA approval, no one really knows how much benefit this drug will produce. The story should have noted that–strongly.

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

The story provides no discussion of potential side effects or harms of this treatment approach, other than the patient’s statement that he has had no side effects. He also called the new intervention “a breeze.”

In truth, because the drug’s safety is being evaluated in this clinical trial, the researchers do not yet know what side effects might occur, a fact the story does not address. Also, there were likely some side effects measured in the animal studies.

Does the story seem to grasp the quality of the evidence?

Not Satisfactory

The story focuses on the use of the treatment in the very first human participant, and it was written before enough time had passed even to know whether the drug would have the intended effect in this one patient. Given that, this is essentially the same as writing a story based on research in laboratory rats. To the writer’s credit, the story does note that much more research will be required before the light-activated drug could receive FDA approval for widespread use. Nonetheless, the overall tone of the story suggests that “the drug’s viral artificial nanoparticles” could be expected to provide effective treatment for “many types of malignant cells.”

Does the story commit disease-mongering?

Satisfactory

The story avoids disease-mongering, noting that ocular melanoma is rare.

Does the story use independent sources and identify conflicts of interest?

Not Satisfactory

There are no independent sources in the story. The only sources are the initial clinical trial patient, the doctor who is conducting the clinical trial and the founding CEO of Aura Biosciences, the drug’s developer.

Does the story compare the new approach with existing alternatives?

Satisfactory

The story mentions four other approaches to dealing with ocular melanoma, including monitoring without immediate treatment, implantation of a radioactive iodine chip, proton beam and gamma knife therapy (neither of which is explained), and surgery to remove either the tumor or the entire eye. This is sufficient to merit a satisfactory rating.

It would have been useful to highlight the existing options–and quantify the outcomes–so readers would have a sense of what we goals we would be shooting for with a new treatment. Also, we also took issue with how the story frames the existing treatment for ocular melanoma by highlighting its negative side effects in one famous patient (Oliver Sacks) against the experimental therapy’s potential, which is still only based on animal studies.

Does the story establish the availability of the treatment/test/product/procedure?

Satisfactory

The author acknowledges that the initial clinical trial, in which the featured patient is participating, will take two more years and that that two additional clinical trials would have to demonstrate safety and efficacy of the drug before it could receive FDA approval. This was a strong point in the story.

Does the story establish the true novelty of the approach?

Satisfactory

The story notes that Aura Biosciences chose to test the experimental drug on ocular melanoma because there currently is no drug useful in treating this disease. It says that the drug’s artificial viral nanoparticles have been shown to “zero in on and bind to many types of malignant cells without harming normal cells” – but only in lab experiments, which suggests that the drug’s use in humans is new.

Does the story appear to rely solely or largely on a news release?

Satisfactory

We could find no evidence that the story relied solely on a news release.

Total Score: 5 of 10 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.